ATNM - שווי פעילות לרווח לפני ריבית, מסים ופחת actiniumpharma.com
Actinium Pharmaceuticals (ATNM) leverages a US-based R&D infrastructure to develop targeted radiopharmaceuticals for the treatment of hematologic malignancies. High business margins are sustained by patent rights for bone marrow transplant preparation agents. The implementation of software robots and automated screening accelerates the release of new drugs, and the current market quotes visualized below show an EV/EBITDA value of 1.53.
Actinium Pharmaceuticals, Inc. - פילוחים אנליטיים ומדדי מפתח (ATNM)
This ratio compares the total enterprise value, including net debt, to operating profit to determine the efficiency of debt coverage. By analyzing the EV/EBITDA ratio from a historical perspective, an investor can assess the overpayment for the assets of Actinium Pharmaceuticals (ATNM), whose development costs for "smart" radiopharmaceuticals for blood cancer therapy require strict liquidity control to minimize default risks.
